Profile data is unavailable for this security.
About the company
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
- Revenue in USD (TTM)0.00
- Net income in USD-175.50m
- Incorporated2015
- Employees171.00
- LocationPliant Therapeutics Inc331 Oyster Point BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 481-6770
- Websitehttps://pliantrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasus Pharma Ltd | 0.00 | -1.19m | 49.04m | -- | -- | -- | -- | -- | -0.1319 | -0.1383 | 0.00 | -0.4762 | 0.00 | -- | -- | -- | -373.32 | -- | -- | -- | -- | -- | -- | -- | -- | -2.51 | -- | -- | -- | -- | -54.23 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 52.65m | 137.00 | -- | 2,022.38 | -- | -- | -108.70 | -108.70 | 0.00 | 74.17 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 41.28m | -3.33m | 57.73m | 91.00 | -- | 2.21 | 45.75 | 1.40 | -0.2331 | -0.2331 | 2.79 | 1.75 | 0.5788 | 1.72 | 3.80 | 453,608.30 | -4.68 | -6.88 | -7.60 | -9.65 | 84.49 | 80.74 | -8.09 | -15.89 | 1.11 | -28.41 | 0.1688 | -- | -4.26 | 1.95 | -3.19 | -- | -29.32 | -- |
| ImmuCell Corp | 27.77m | 2.32m | 59.97m | 70.00 | 25.62 | 2.01 | 11.95 | 2.16 | 0.2588 | 0.2588 | 3.09 | 3.29 | 0.6159 | 1.90 | 11.42 | 402,453.60 | 5.15 | -5.35 | 5.69 | -5.77 | 40.93 | 36.02 | 8.37 | -11.87 | 1.76 | 6.47 | 0.2415 | -- | 51.64 | 14.06 | 62.65 | -- | -19.66 | -- |
| Rafael Holdings Inc | 1.03m | -31.33m | 62.12m | 21.00 | -- | 0.738 | -- | 60.36 | -0.8471 | -0.8471 | 0.0284 | 1.63 | 0.0107 | -- | 3.35 | 49,000.00 | -32.33 | -45.03 | -37.62 | -51.75 | 89.70 | -- | -3,034.89 | -8,772.74 | 3.98 | -- | 0.0074 | -- | 43.96 | -28.51 | 11.30 | -- | -47.65 | -- |
| Janel Corp | 207.44m | 5.03m | 62.88m | 353.00 | 12.69 | 2.44 | 7.31 | 0.3031 | 4.18 | 4.18 | 172.09 | 21.75 | 1.47 | 32.80 | 4.14 | 587,657.30 | 4.02 | 1.76 | 13.35 | 5.33 | 31.33 | 26.69 | 2.73 | 0.9608 | 0.7013 | 3.10 | 0.3913 | 0.00 | 13.24 | 20.27 | 2,155.61 | -- | -14.58 | -- |
| LifeVantage Corp | 210.05m | 7.86m | 63.07m | 232.00 | 8.22 | 1.91 | 5.85 | 0.3003 | 0.5998 | 0.5998 | 16.16 | 2.58 | 3.24 | 2.45 | 96.73 | 905,370.70 | 12.12 | 9.17 | 18.91 | 14.08 | 78.75 | 80.73 | 3.74 | 2.93 | 1.03 | -- | 0.00 | 35.06 | 14.17 | -0.3794 | 233.84 | -3.22 | -12.55 | -- |
| Pelthos Therapeutics Inc | 7.41m | -23.58m | 69.47m | 4.00 | -- | 1.19 | -- | 9.38 | -17.09 | -17.09 | 6.02 | 18.85 | 0.1152 | -- | -- | 1,851,500.00 | -36.68 | -- | -47.05 | -- | 68.73 | -- | -318.41 | -- | 1.04 | -12.32 | 0.00 | -- | -- | -- | -7.78 | -- | -- | -- |
| Pliant Therapeutics Inc | 0.00 | -175.50m | 71.28m | 171.00 | -- | 0.3559 | -- | -- | -2.87 | -2.87 | 0.00 | 3.26 | 0.00 | -- | -- | 0.00 | -48.60 | -38.70 | -52.81 | -41.26 | -- | -- | -- | -1,044.87 | -- | -- | 0.1319 | -- | -100.00 | -- | -30.35 | -- | 31.90 | -- |
| MindWalk Holdings Corp | 15.07m | -22.87m | 72.37m | 102.00 | -- | 5.48 | -- | 4.80 | -0.6354 | -0.617 | 0.3533 | 0.2831 | 0.4745 | 6.67 | 4.50 | -- | -72.01 | -32.32 | -90.53 | -36.45 | 58.50 | 55.79 | -151.78 | -100.97 | 4.09 | -23.68 | 0.17 | -- | 0.0082 | 11.77 | -11.25 | -- | 10.37 | -- |
| Assertio Holdings Inc | 137.35m | -28.92m | 74.95m | 58.00 | -- | 0.7084 | 33.96 | 0.5457 | -4.71 | -4.71 | 20.93 | 16.49 | 0.4611 | 1.35 | 1.47 | 2,368,138.00 | -9.71 | -15.74 | -17.07 | -24.19 | 68.16 | 82.29 | -21.06 | -42.01 | 1.43 | -- | 0.2702 | -- | -17.83 | -11.45 | 93.50 | -- | -- | -- |
| Scilex Holding Co | 40.36m | -375.84m | 75.74m | 30.00 | -- | -- | -- | 1.88 | -33.18 | -33.18 | 4.08 | -28.88 | 0.2145 | 7.27 | 1.85 | 350,956.50 | -177.73 | -- | -- | -- | 68.59 | 75.06 | -828.56 | -176.54 | 0.0429 | -3.76 | -- | -- | 21.07 | 21.89 | 56.40 | -- | -49.14 | -- |
| Polypid Ltd | 0.00 | -34.22m | 77.85m | 57.00 | -- | 5.07 | -- | -- | -2.98 | -2.98 | 0.00 | 0.9237 | 0.00 | -- | -- | 0.00 | -147.37 | -90.05 | -241.51 | -109.86 | -- | -- | -- | -- | -- | -22.38 | 0.1359 | -- | -- | -- | -21.61 | -- | -38.71 | -- |
| NovaBay Pharmaceuticals Inc | 2.83m | -7.95m | 88.33m | 14.00 | -- | -- | -- | 31.21 | -1.58 | 0.5377 | 0.555 | 0.2718 | 0.7686 | -- | 5.28 | 202,142.90 | -215.92 | -61.58 | -404.37 | -83.79 | 54.56 | 59.49 | -280.92 | -77.39 | -- | -91.56 | 0.0836 | -- | -33.58 | 8.19 | 48.52 | -- | -20.59 | -- |
Data as of Feb 10 2026. Currency figures normalised to Pliant Therapeutics Inc's reporting currency: US Dollar USD
46.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Sep 2025 | 6.00m | 9.77% |
| Woodline Partners LPas of 30 Sep 2025 | 4.50m | 7.33% |
| Point72 Asset Management LPas of 30 Sep 2025 | 4.36m | 7.10% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.46m | 4.00% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 2.37m | 3.86% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2025 | 2.13m | 3.47% |
| Citadel Advisors LLCas of 23 Jan 2026 | 2.10m | 3.42% |
| Redmile Group LLCas of 30 Sep 2025 | 1.59m | 2.59% |
| BML Capital Management LLCas of 31 Dec 2025 | 1.55m | 2.52% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.35m | 2.20% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
